Victoria Johnson

This rheumatology month in review emphasizes new data from the ACR Convergence.

A compilation of 13 trials presented as late-breaking data at ACR Convergence 2025.

The rheumatology month in review emphasizes new data presented at the 2025 ACR Convergence.

Ianalumab significantly reduces Sjögren disease activity, meeting the primary outcome in recent phase 3 trials.

Mepolizumab shows significant real-world benefits in reducing end-organ dysfunction.

Switching to an IL-17 inhibitor after TNF inhibitor failure showed no superior benefits for axial spondyloarthritis.

TENS combined with physical therapy significantly alleviates fibromyalgia pain and fatigue.

A recent exploratory analysis reveals significant kidney B-cell depletion by the recently approved drug.

Telitacicept significantly alleviates Sjögren disease symptoms over 48 weeks, outperforming placebo with a favorable safety profile in a phase 3 trial.

View slated expert interviews and 6 clinical RA, PsA, and lupus trials to watch at ACR 2025.

However, a notable higher rate of treatment-related adverse events warrants caution.

Sonelokimab meets ACR50 primary endpoint in a phase 2 trial.

Q3 2025 saw a number of exciting approvals and data on promising therapies in development.

Q3 2025 saw several new first targeted therapies for rare and more individualized indications in a number of fields.

The rheumatology month in review emphasizes new approvals and the latest comparative research.

Risankizumab shows significant and lasting improvements in psoriatic arthritis symptoms, addressing multiple disease domains and enhancing patient quality of life.

Upadacitinib reduced glucocorticoid doses and improved disease activity over 104 weeks.

Study data favored the placebo group, although differences were not clinically meaningful.

Combining golimumab with methotrexate reduced corticosteroid reliance and maintained efficacy in psoriatic arthritis.

The rheumatology month in review emphasizes new approvals and best-in-class efficacy data.

The FDA has approved the therapy, marketed as Wayrilz, a new treatment for chronic immune thrombocytopenia.

Regeneron is planning a BLA submission for the first quarter of 2026.

This FDA News Month in Review provides a round-up of regulatory decisions from August 2025.

Santerus AG is preparing to initiate clinical trials of its blood purification technology in a variety of indications.

Despite high cardiovascular risk with the 2 comorbidities, no beneficial effect was seen with colchicine.

In this feature, 3 experts discuss the management of 2 overlapping conditions: psoriasis and psoriatic arthritis.

A recent study reveals gout patients face higher chronic opioid prescription rates.

Rosnilimab shows promising long-term efficacy in treating moderate-to-severe rheumatoid arthritis.

The therapy, marketed as Tonmya, is a sublingual formulation of cyclobenzaprine HCl.